BIOQX® L(-)-Fucose (6-Deoxy-L-galactose)

A rare deoxyhexose monosaccharide with pivotal roles in glycobiology — from blood group antigens to immunological signaling and microbiome interactions. Supplied by an FDA-inspected, GMP-certified manufacturer.

6-Deoxy-L-galactose
≥ 98% Purity
CAS 2438-80-4
GMP Grade
RUO
Catalog No. MBCA006002

Product overview

L-(−)-Fucose (6-Deoxy-L-galactose, CAS 2438-80-4) is a naturally occurring deoxyhexose monosaccharide, lacking the 6-hydroxyl group found in most common sugars.

Present on the outer surface of virtually all mammalian cells, fucose decorates N-linked and O-linked glycoproteins and glycolipids as a terminal or branching modification. This peripheral position makes it a primary recognition signal in a vast array of biological processes central to glycobiology research.

As a leading L-Fucose supplier in Europe, BIOQX® provides pharmaceutical-grade L-Fucose from a GMP-certified, FDA-inspected manufacturing facility, serving research institutes, CROs, and biopharmaceutical companies across Germany and the EU.

Structural uniqueness

The C6-methyl group confers distinct conformational preferences and hydrophobic character absent in other common hexoses.

Metabolic incorporation

Exogenous L-fucose is efficiently salvaged and activated to GDP-fucose, feeding directly into the Golgi fucosylation pathway.

Biosynthetic gateway

Precursor for numerous fucosylated epitopes central to immune recognition, including Lewis antigens and sialyl-Lewis X.

BULK PACKAGING

8 kg drum · Room temp. storage

PRODUCT QUALITY

High-purity white crystalline powder

Fucosylation

Pathway

L-Fucose enters cells via specific transporters and is activated by fucokinase (FUK) and GDP-fucose pyrophosphorylase (FPGT), channeling into the nucleotide-sugar pool as GDP-beta-L-fucose — the universal donor for all cellular fucosyltransferases.

L-Fucose (exogenous) fucokinase Fucose-1-P (phosphorylated) FPGT GDP-β-L-Fucose (active donor) FUTs 1–11 Fucosylated Glycans (cell-surface display) ABO · Selectin · Immune · Cancer

Specifications

PropertyValueNotes
Molecular FormulaC6H12O5Deoxyhexose — OH replaced by H at C-6
Molecular Weight164.16 g/molConfirmed by HRMS
CAS Number2438-80-4L-configuration enantiomer
Melting Point150–153 °CLiterature value
Boiling Point~211 °CRough estimate
Density1.1738 g/cm³Rough estimate
Optical Rotation[α]D −75° to −77°L-configuration, aqueous solution
Solubility (H2O)0.1 g/mLClear, colorless solution
pKa12.50 ± 0.20Predicted
AppearanceWhite crystalline powder—
StorageRoom temperatureStable under ambient conditions
WGK Germany3HS Code 29400090

Pricing & Availability

Lead Time ~2 Weeks

Standard delivery from stock. High-purity pharmaceutical-grade material is produced in dedicated GMP batches to ensure consistent quality. Contact us for urgent requirements.

Full Documentation Included

Every lot ships with Certificate of Analysis (COA), MSDS, and batch-specific purity data. Custom specifications and additional documentation available on request.

Small Scale

0–1 kg

2.499 €

per kg · netto

Research quantity

Mid Scale

1–10 kg

2.299 €

per kg · netto

Save 8%

Pilot Scale

10–100 kg

2.099 €

per kg · netto

Save 16%

Industrial Scale

ab 100 kg

1.899 €

per kg · netto

Best value · Save 24%

Research Applications

Carbohydrate Chemistry

Glycobiology & Lectin Studies

Used in Fucose Glykoforschung to study fucose-binding lectins including selectins and DC-SIGN. Key applications include competitive inhibition assays, fucosylation-dependent cell adhesion studies, and synthesis of Lewis blood group antigens.

Immunotherapy Research

Immunology & Inflammation

Sialyl-Lewis X and related fucosylated epitopes are E/P-selectin ligands mediating leukocyte rolling. L-Fucose CAS 2438-80-4 is essential for synthesizing these antigens and studying leukocyte trafficking and inflammation cascade pathways.

Oncology

Cancer Biology

Aberrant hyperfucosylation is a hallmark of hepatocellular carcinoma, pancreatic cancer, and other malignancies. L-Fucose enables synthesis of tumor-associated carbohydrate antigens (TACAs) and glycan-based vaccine epitopes for oncology research

Antibody Engineering

Biopharmaceutical Development

Core fucosylation of IgG antibodies significantly affects FcgRIII binding affinity and ADCC activity. L-Fucose supplementation is a validated strategy for optimizing monoclonal antibody therapeutics and next-generation biologics manufacturing.

Microbiology

Microbiome & Host-Pathogen

Gut bacteria such as Bacteroides thetaiotaomicron harvest host mucosal fucose for colonization. L-Fucose is used in studying fucosylation-dependent colonization resistance, microbiome homeostasis, and pathogen adhesion inhibition strategies.

Chemical Biology

Metabolic Labeling & Imaging

Modified fucose analogues (e.g., 6-azido-L-fucose, Ac4FucAz) leverage the cellular salvage pathway initiated by L-Fucose for bioorthogonal click-chemistry labeling of cell-surface glycoconjugates in live cells and model organisms.

Manufacturing & Quality

As a GMP-certified manufacturer, we supply L-Fucose in bulk quantities with full traceability and lot-specific documentation. Whether you need research quantities or large-scale industrial supply, we ship reliably from our production facility in China to customers across Europe and beyond.

FDA inspection — zero observations

Successfully passed an FDA on-site inspection in July 2024 with zero Form 483 observations.

✓ FDA Inspected · July 2024 · 0 Form 483

Drug Production License

Holding a valid, government-issued Drug Production License — enabling compliant supply of pharmaceutical-grade raw materials to regulated markets worldwide.

✓ Licensed Drug Manufacturer

  1. 1

    Becker, D.J. & Lowe, J.B. (2003)

    Fucose: biosynthesis and biological function in mammals

    Glycobiology · Vol. 13, No. 7, pp. 41R–53R · DOI: 10.1093/glycob/cwg054

  2. 2

    Schneider, M. et al. (2017)

    The human exome reveals a role of fucosylation in cancer progression

    Nature Communications · Vol. 8, 14126 · DOI: 10.1038/ncomms14126

  3. 3

    Shields, R.L. et al. (2002)

    Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and ADCC

    Journal of Biological Chemistry · Vol. 277, pp. 26733–26740 · DOI: 10.1074/jbc.M202069200

  4. 4

    Goto, Y. et al. (2014)

    Innate lymphoid cells regulate intestinal epithelial cell glycosylation

    Science · Vol. 345, Issue 6202 · DOI: 10.1126/science.1254009

  5. 5

    Laughlin, S.T. & Bertozzi, C.R. (2009)

    In vivo imaging of Caenorhabditis elegans glycans

    ACS Chemical Biology · Vol. 4, No. 12, pp. 1068–1072 · DOI: 10.1021/cb900254y

Key Literature References

Scroll to Top